Arcus Biosciences, Inc. RCUS

Updated: 13 Jun 2026

NYSE | Biotech | Cancer immunotherapies and combination treatments

No signal published yet

We already track Arcus Biosciences and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Arcus Biosciences free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NYSE
Type
Biotech
Sector
Cancer immunotherapies and combination treatments
We're already tracking Arcus Biosciences, Inc. — here are the latest events we've registered

Recent News

  • In May 2026, Arcus reported first-quarter financial results with a cash position of $876 million, providing a runway into the second half of 2028. The company highlighted progress in its Phase 3 PEAK-1 study for casdatifan and announced plans to initiate a new Phase 3 study in first-line kidney cancer by the end of 2026.

What Firelda Watch includes for Arcus Biosciences, Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Arcus Biosciences, Inc. will be delivered in the same format.

Sample analyses in the same sector

Sample full analysis — same format your watchlist gets

Moderna, Inc.
MRNA
HOLD
AstraZeneca PLC
AZN
HOLD
Calliditas Therapeutics
CALT
NEUTRAL
Ionis Pharmaceuticals, Inc.
IONS
HOLD
Exelixis, Inc.
EXEL
HOLD

Biotech

More companies in this sector

Want to follow Arcus Biosciences, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Arcus Biosciences free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Arcus Biosciences, Inc. RCUS
Arcus Biosciences — follow and we'll monitor it
Follow Arcus Biosciences free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.